# David Meeker, Former President and CEO, Genzyme



Dr. Meeker joined KSQ Therapeutics as CEO in September 2017. A Cambridge-based start-up, KSQ is pioneering CRISPR genome-screening technology to identify targets for drugs to treat cancer and immune mediated diseases. Dr. Meeker is the former Executive Vice President of Sanofi and CEO of Genzyme, a Sanofi company, the specialty care global business unit of Sanofi which focuses on rare diseases, multiple sclerosis, oncology, and immunology. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to the merger with Sanofi in 2011, Dr. Meeker was Chief Operating Officer, responsible for Genzyme’s commercial organization, overseeing its business units¸ country management organization and global market access functions. In October 2011 he was appointed President and Chief Executive Officer of Genzyme, a Sanofi company. Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr. Meeker received his MD from the University of Vermont Medical School. He completed his Internal Medicine Training at Harvard’s Beth Israel Hospital and his Pulmonary Critical Care Fellowship at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.